PT-141 (Bremelanotide) Future Formulations & Pipeline

HealthRX.com

Vyleesi is the only approved bremelanotide; no oral form exists

Print or save as PDF

Key numbers

  • 1.75 mgApproved single as-needed dose strength of Vyleesi, the only approved form, for premenopausal women with acquired HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 45 minutesMinimum time before anticipated sexual activity to use an as-needed Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Women on Vyleesi reporting nausea in pooled phase 3 trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 6 mmHgMaximal systolic blood pressure increase after a dose (diastolic increase was 3 mmHg)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

Registered clinical studies of bremelanotide

ClinicalTrials.gov lists 10 registered studies that name bremelanotide as an intervention as of 2026-11-11. Of these, 0 are recruiting, 9 are completed and 3 are phase 3 studies.

Registered clinical studies of bremelanotide: the figures
MeasureValue
Registered studies10
Recruiting now0
Not yet recruiting0
Completed9
Terminated, withdrawn or suspended0
Phase 3 (including phase 2/3)3
Phase 2 (including phase 1/2)4
Phase 11

Source: NIH National Library of Medicine, ClinicalTrials.gov, data as of Nov 11, 2026

How this was calculated

Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.

Scope: Studies whose intervention field matches bremelanotide, any condition, any country, all statuses

A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.

Download the data (CSV)

From the public record

Published papers mentioning bremelanotide

PubMed indexes 96 papers that mention bremelanotide in the title or abstract, 76 of them published from 2016 to 2025. The count for 2025 is 12 and for 2024 is 8.

Published papers mentioning bremelanotide: the figures
MeasureValueNote
Papers indexed, all years96
Published 2016 to 202576
Published in 202512
Published in 20248
Busiest year since 2016202214 papers

Source: NIH National Library of Medicine, PubMed, data as of Nov 11, 2026

How this was calculated

Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.

Scope: PubMed records with 'bremelanotide' in the title or abstract, all article types and species

A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.

Download the data (CSV)

From the public record

Patents and generic approvals for bremelanotide

The FDA Orange Book lists 0 approved generic applications for bremelanotide across 1 listed product. 4 listed patents have not yet expired, the last on 2041-04-29.

Patents and generic approvals for bremelanotide: the figures
MeasureValue
Brand-name applications (NDA)1
Approved generic applications (ANDA)0
Listed patents not yet expired4
Latest listed patent expiry2041-04-29
Earliest approval date on file2019-06-21
Products not marked discontinued1 of 1

Source: FDA, Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), data as of Oct 9, 2026

How this was calculated

Selected Orange Book products whose only active ingredient is this substance, then counted applications by type and the distinct patents and exclusivities listed against them. Expired patents are left out.

Scope: All single-ingredient bremelanotide products in the Orange Book, every brand and strength, files dated 2026-10-09

An approved generic or an expired patent does not show that a generic is on sale. Launch timing also depends on litigation, settlements and supply. Biologics and compounded products are not in the Orange Book.

Download the data (CSV)

At a glance

  • Approved form / 1.75 mg subcutaneous autoinjector (Vyleesi) [1]
  • Approval / June 21, 2019, NDA 210557 [2]
  • Approved use / Acquired, generalized HSDD in premenopausal women [1]
  • Other route in human data / Intranasal, in small early studies [3][4]
  • Oral or depot product / None approved [1]
  • Peak and half-life / Median Tmax about 1 hour; mean terminal half-life about 2.7 hours [1]

What is approved right now

Vyleesi is the FDA-approved bremelanotide product: 1.75 mg subcutaneously in a prefilled autoinjector, prescription only, NDA 210557, approved June 21, 2019, now held by Cosette Pharmaceuticals [1][2]. It is indicated for premenopausal women with acquired, generalized HSDD — low sexual desire causing marked distress or interpersonal difficulty not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug — and the label states it is not indicated for postmenopausal women, for men, or to enhance sexual performance [1].

The approved regimen is 1.75 mg subcutaneously in the abdomen or thigh, used as needed at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and more than 8 doses per month not recommended [1]. The label describes only this autoinjector; no oral or depot bremelanotide product is approved [1]. Products sold as compounded or research-use 'PT-141' are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][5].

Questions worth asking

Choose the questions you want to keep

What the early intranasal studies found

The human data on a non-injection route come from small intranasal studies. In 2004, Diamond and colleagues gave intranasal PT-141 to healthy men and to men with mild-to-moderate erectile dysfunction; erectile response was significantly greater than placebo at doses above 7 mg, and flushing and nausea were the most common adverse events [4]. In 2006, a single 20 mg intranasal dose was given to 18 premenopausal women with female sexual arousal disorder in a double-blind crossover study, and more women reported moderate or high sexual desire than after placebo (P=0.0114) [3]. The label's alcohol interaction study, a clinical pharmacology study, also used a 20 mg intranasal dose, about 2.5-fold the Cmax of the approved 1.75 mg subcutaneous dose [1].

Safety profile of the approved injection

In the pooled phase 3 trials (1,247 women), nausea was reported by 40.0% on Vyleesi vs 1.3% on placebo, flushing 20.3% vs 0.3%, injection site reactions 13.2% vs 8.4% and headache 11.3% vs 1.9%; 13% used anti-nausea medicine, and discontinuation because of adverse reactions was 18% vs 2% [1]. In a single-dose study of 228 healthy women, pre-treatment with 8 mg oral ondansetron did not reduce nausea, and the label does not recommend it [1]. Maximal blood pressure increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose, with a heart rate reduction of up to 5 beats per minute [1].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the label, how long before anticipated sexual activity should the approved 1.75 mg dose be used?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

Is an oral form of PT-141 available?
No oral bremelanotide product is approved. The approved product is a 1.75 mg subcutaneous autoinjector used as needed at least 45 minutes before sexual activity [1].
What did the early intranasal bremelanotide studies find?
A 2004 study in men found a significant erectile response versus placebo at intranasal doses above 7 mg, with flushing and nausea the most common side effects [4]. A 2006 study of 18 premenopausal women found more reported moderate or high desire after a single 20 mg intranasal dose than after placebo (P=0.0114) [3].
Is compounded or research PT-141 the same as Vyleesi?
No. Vyleesi is the FDA-approved bremelanotide product; PT-141 sold as a compounded or research-use peptide is not an FDA-approved drug, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][5].
Is a long-acting or depot bremelanotide approved?
No. The label describes single as-needed 1.75 mg subcutaneous doses, no more than one in 24 hours and no more than 8 a month [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

When to inject PT-141?

Vyleesi is used as needed: a 1.75 mg subcutaneous injection in the abdomen or thigh, given at least 45 minutes before anticipated sexual activity. No more than one dose is allowed in 24 hours, and more than 8 doses per month is not recommended.

What is bremelanotide nasal spray?

No bremelanotide nasal spray is approved. An intranasal form was tested in small early studies, including a 2004 study in men where doses above 7 mg produced a significantly greater erectile response than placebo, but that route was never approved. The only approved product is the 1.75 mg subcutaneous autoinjector, Vyleesi.

References

Show all 6 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. U.S. Food and Drug Administration.
  3. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638.
  4. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-9.
  5. Official web page.
  6. Clayton AH, Kingsberg SA, Goldstein I. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sex Med. 2018;6(2):59-74.
Evidence overview for pt 141: PT-141 (Bremelanotide) Future Formulations & Pipeline